Draper entered a multi-year strategic technology collaboration with Kite, a Gilead Company, to enhance Kite’s development of cell therapies using Draper’s engineering services and portfolio of cell bioprocessing technologies. Draper’s technologies will enable Kite to improve next-generation cell therapies and increase cell manufacturing throughput.

Kite will have access to technology and engineering services for developing cancer immunotherapy products with a primary focus on genetically engineered T cell therapies. Kite is the first company with multiple approved chimeric antigen receptor (CAR) T cell therapies.

Draper has developed technology that advances the manufacturing efficiency of cell and gene therapies by leveraging expertise in the areas of precision microfluidics, gene delivery, integrated sensing, customization and automation.

Because cell and gene therapies are often patient specific, there is a critical unmet need for better manufacturing solutions. For example, T cell therapies for cancer involve collecting T cells from a patient’s blood, genetically modifying them to recognize and attack cancer cells and then reinfusing them to the patient. Given the size of the patient population that could benefit from these potentially curative treatments, efficient and scalable manufacturing is essential.

“Over the next decade, cell and gene therapies are poised to make groundbreaking improvements in health care on a worldwide basis. Draper applauds Kite for its leadership in cell therapy and we look forward to supporting its effort to expand novel treatments for patients living with cancer,” said Tara Clark, Vice President of Commercial Business at Draper.